VECT-HORUS VECT-HORUS is a biotech company that develops peptide-based vectors to facilitate the delivery of drugs or imaging agents into the brain and to tumors. | ![]() Gamida Cell Gamida Cell develops stem cell therapy technologies and products for the treatment of blood cancers, autoimmune and metabolic diseases. | ![]() OncoDNA OncoDNA is a cancer theranostic company which uses a combination of the relevant molecular technologies to support oncologists in their treatment decisions for patients. | ||
Founding Date | Founding Date 2014 | Founding Date 2005 | Founding Date 1998 | Founding Date 2012 |
Type | Type Public | Type Private | Type Public | Type Private |
Tags | ||||
Locations | Locations San Diego, US HQ | Locations Marseille, FR HQ | Locations Boston, US HQ Jerusalem, IL | Locations Charleroi, BE HQ |
Employees | Employees N/A | Employees 512% increase | Employees 143175% increase | Employees 502% increase |
Valuation ($) | Valuation ($) 13.8 m | Valuation ($) N/A | Valuation ($) 4.3 m | Valuation ($) N/A |
Financial | ||||
Cost of goods | Cost of goods $319.5k (FY, 2024) | Cost of goods N/A | Cost of goods $1.5m (FY, 2023) | Cost of goods N/A |
Net income | Net income ($2.1m) (FY, 2024) | Net income N/A | Net income ($63m) (FY, 2023) | Net income N/A |
Funding | ||||
Latest funding round | Latest funding round N/A | Latest funding round $ 14.5m (over 5 years ago) | Latest funding round N/A | Latest funding round $ 20.6m (over 6 years ago) |
Total funding raised | Total funding raised $ 2m | Total funding raised $ 29.4m | Total funding raised $ 128.3m | Total funding raised $ 29.8m |
VECT-HORUS is a biotech company that develops peptide-based vectors to facilitate the delivery of drugs or imaging agents into the brain and to tumors.
View company
Gamida Cell develops stem cell therapy technologies and products for the treatment of blood cancers, autoimmune and metabolic diseases.
View company
OncoDNA is a cancer theranostic company which uses a combination of the relevant molecular technologies to support oncologists in their treatment decisions for patients.
View company